OPL 0101
Alternative Names: CT 101 - Valo Health; OIL 2; OMCP-mutIL2; OPL-0101Latest Information Update: 28 Apr 2023
Price :
$50 *
At a glance
- Originator Courier Therapeutics
- Developer Valo Health
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action CD8 positive T lymphocyte stimulants; Interleukin 2 replacements; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer